Literature DB >> 10888602

A novel ryanodine receptor mutation and genotype-phenotype correlation in a large malignant hyperthermia New Zealand Maori pedigree.

R L Brown1, A N Pollock, K G Couchman, M Hodges, D O Hutchinson, R Waaka, P Lynch, T V McCarthy, K M Stowell.   

Abstract

Malignant hyperthermia (MH) is a pharmacogenetic disorder that predisposes to a sometimes fatal hypermetabolic reaction to halogenated anaesthetics. MH is considered to originate from abnormal regulation of skeletal muscle Ca(2+) release. Current diagnosis of MH susceptibility (MHS) relies on in vitro contracture testing (IVCT) of skeletal muscle. The ryanodine receptor (RYR1) encoding the major Ca(2+) release channel in the skeletal muscle sarcoplasmic reticulum has been shown to be mutated in a number of MH pedigrees. The large Maori pedigree reported here is the largest MHS pedigree investigated to date and comprises five probands who experienced clinical episodes of MH and 130 members diagnosed by the IVCT. Sequencing of the 15 117 bp RYR1 cDNA in a MHS individual from this pedigree identified a novel C14477T transition that results in a Thr4826 to Ile substitution in the C-terminal region/transmembrane loop of the skeletal muscle ryanodine receptor. This is the first mutation in the RyR1 C-terminal region associated solely with MHS. Although linkage analysis showed strong linkage (max LOD, 11.103 at theta = 0.133) between the mutation and MHS in the pedigree using the standardized European IVCT phenotyping protocol, 22 MHS recombinants were observed. The relationship between the IVCT response and genotype was explored and showed that as IVCT diagnostic cut-off points were made increasingly stringent, the number of MHS discordants decreased with complete concordance between the presence or absence of the C14477T mutation and MHS and MH normal phenotypes, respectively, using a cut-off of 1.2 g tension at 2.0 mM caffeine and 1.8 g tension at 2.0% halothane. Many MHS pedigrees investigated have been excluded from linkage to the RYR1 gene on the basis of a small number of recombinants; however, the linkage analysis reported here suggests that other recombinant families excluded from linkage to the RYR1 gene may actually demonstrate linkage as the number of members tested within the pedigrees increases. The high number of discordants observed using the standardized diagnostic cut-off points is likely to reflect the presence of a second MHS susceptibility locus in the pedigree.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10888602     DOI: 10.1093/hmg/9.10.1515

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  16 in total

1.  Excitation--contraction uncoupling by a human central core disease mutation in the ryanodine receptor.

Authors:  G Avila; J J O'Brien; R T Dirksen
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

2.  Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death.

Authors:  N Sumitomo; K Harada; M Nagashima; T Yasuda; Y Nakamura; Y Aragaki; A Saito; K Kurosaki; K Jouo; M Koujiro; S Konishi; S Matsuoka; T Oono; S Hayakawa; M Miura; H Ushinohama; T Shibata; I Niimura
Journal:  Heart       Date:  2003-01       Impact factor: 5.994

3.  Role of amino-terminal half of the S4-S5 linker in type 1 ryanodine receptor (RyR1) channel gating.

Authors:  Takashi Murayama; Nagomi Kurebayashi; Toshiharu Oba; Hideto Oyamada; Katsuji Oguchi; Takashi Sakurai; Yasuo Ogawa
Journal:  J Biol Chem       Date:  2011-08-23       Impact factor: 5.157

4.  Identical de novo mutation in the type 1 ryanodine receptor gene associated with fatal, stress-induced malignant hyperthermia in two unrelated families.

Authors:  Linda Groom; Sheila M Muldoon; Zhen Zhi Tang; Barbara W Brandom; Munkhuu Bayarsaikhan; Saiid Bina; Hee-Suk Lee; Xing Qiu; Nyamkhishig Sambuughin; Robert T Dirksen
Journal:  Anesthesiology       Date:  2011-11       Impact factor: 7.892

5.  Gene dose influences cellular and calcium channel dysregulation in heterozygous and homozygous T4826I-RYR1 malignant hyperthermia-susceptible muscle.

Authors:  Genaro C Barrientos; Wei Feng; Kim Truong; Klaus I Matthaei; Tianzhong Yang; Paul D Allen; José R Lopez; Isaac N Pessah
Journal:  J Biol Chem       Date:  2011-12-02       Impact factor: 5.157

6.  Mice expressing T4826I-RYR1 are viable but exhibit sex- and genotype-dependent susceptibility to malignant hyperthermia and muscle damage.

Authors:  Benjamin Yuen; Simona Boncompagni; Wei Feng; Tianzhong Yang; Jose R Lopez; Klaus I Matthaei; Samuel R Goth; Feliciano Protasi; Clara Franzini-Armstrong; Paul D Allen; Isaac N Pessah
Journal:  FASEB J       Date:  2011-11-30       Impact factor: 5.191

7.  Malignant hyperthermia-associated mutations in the S2-S3 cytoplasmic loop of type 1 ryanodine receptor calcium channel impair calcium-dependent inactivation.

Authors:  Angela C Gomez; Timothy W Holford; Naohiro Yamaguchi
Journal:  Am J Physiol Cell Physiol       Date:  2016-08-24       Impact factor: 4.249

8.  Single-amino-acid deletion in the RYR1 gene, associated with malignant hyperthermia susceptibility and unusual contraction phenotype.

Authors:  N Sambuughin; S McWilliams; A de Bantel; K Sivakumar; T E Nelson
Journal:  Am J Hum Genet       Date:  2001-05-29       Impact factor: 11.025

9.  Screening for mutations in the RYR1 gene in families with malignant hyperthermia.

Authors:  Viviane P Muniz; Helga C A Silva; Ana Maria C Tsanaclis; Mariz Vainzof
Journal:  J Mol Neurosci       Date:  2003       Impact factor: 3.444

10.  Antibody probe study of Ca2+ channel regulation by interdomain interaction within the ryanodine receptor.

Authors:  Shigeki Kobayashi; Takeshi Yamamoto; Jerome Parness; Noriaki Ikemoto
Journal:  Biochem J       Date:  2004-06-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.